Mrinalini Dey DrMiniDey
1 week ago
After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibitor over cycling to second TNFi. ASAS40 responses at Week 24 similar with both strategies, supporting individualised treatment decisions. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey
1 week ago
Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA
sheila RHEUMarampa
1 week ago
FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h
Antoni Chan MD (Prof) synovialjoints
1 week ago
Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026
Antoni Chan MD (Prof) synovialjoints
1 week ago
Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026
Antoni Chan MD (Prof) synovialjoints
1 week ago
Day 2 of #EULAR2026 Studies to look forward today in #axSpA: new classification criteria performance, sex differences in disease progression, early disease treatment data, primary care education to reduce delays to diagnosis @RheumNow
sheila RHEUMarampa
1 week ago
Roc-SpA study
Active axSpA dse + inad response to TNFi ➡️switch or cycled
No significant diff in ASDAS40 at wk24 bet IL-17i & 2nd TNFi
Switching to IL-17i not superior to cycling to 2nd TNFi after inad. response to 1st TNFi
Shared decision is key
AbsOP0235 @RheumNow #EULAR2026 https://t.co/3UP37IEgXv
Mrinalini Dey DrMiniDey
1 week ago
#OP0236: a look at the revised 2025 ASAS-SPARTAN classification criteria for axSpA from the global CLASSIC cohort. The updated criteria achieved 79.5% sensitivity & 90.4% specificity, with MRI & radiographic sacroiliitis remaining central to classification. #EULAR2026 @RheumNow https://t.co/rVIqyCmB8K
Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the biological, waits, returns. The pain persists.
Nelly ZIADE 🍀 Nellziade
1 week 1 day ago
📈 Do SIJ lesions progress in #axSpA?
DESIR cohort (n=649, 10yrs):
Yes, slowly, but bDMARDs reduce erosion progression
#OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4
Nelly ZIADE 🍀 Nellziade
1 week 1 day ago
🔍 Best imaging outcome for #axSpA structural change?
SPACE cohort (n=332): MRI-SIJ fat lesions most sensitive to change
#OP0103 #EULAR2026 @RheumNow https://t.co/His1BGYmEW
Nelly ZIADE 🍀 Nellziade
1 week 1 day ago
🖥️ Can MRI-based synthetic CT detect spinal progression in #axSpA?
COPECARE (n=25, 1yr): sCT matches ldCT with no radiation
#OP0104 #EULAR2026 @RheumNow https://t.co/pe9wSMXXZQ
Nelly ZIADE 🍀 Nellziade
1 week 1 day ago
🔍 Is #axSpA overdiagnosed locally?
IMPROVE-axSpA prosp study (n=969):
Yes!
Only 54% locally confirmed centrally
#OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB
sheila RHEUMarampa
1 week 1 day ago
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA:
Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts
Males ⬆️rate of xray prog(msasss)
Sex diffs exist in SpA
Need for sex-specific mgt
AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v
Nelly ZIADE 🍀 Nellziade
1 week 1 day ago
♂♀ Does sex matter in #axSpA long-term?
GESPIC (n=525,10y):
Yes! ♂ less symptoms but 2x more spinal progression
#OP0101 #EULAR2026 @RheumNow https://t.co/znFXWyrfZl
